Payment overview · 2025
General Payments
$1,734.48
105 reported records · 14 companies
Healthcare provider profile · identity verified
Paul Martis, MD
Allopathic & Osteopathic Physicians|Family Medicine · OLATHE, KS · NPI 1508154659
Verified facts
What the public records show
CMS Open Payments records show Paul Martis, MD received $1,734.48 in general payments during 2025 across 105 reported records.
ABBVIE INC. accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Wegovy.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $559.17 | 32.2% | 46 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $241.01 | 13.9% | 13 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $207.34 | 11.9% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $182.73 | 10.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $164.81 | 9.5% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $144.67 | 8.3% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.40 | 3.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.45 | 2.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.12 | 2.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.91 | 2.0% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $19.43 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.52 | 1.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.71 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.21 | 0.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,734.48 | 105 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $288.22 | 23 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $241.01 | 13 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $207.34 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $200.29 | 14 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $182.73 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $158.72 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $144.67 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $107.19 | 16 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $79.94 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $69.11 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $48.25 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.12 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.91 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $7.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $6.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.21 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 440 | 60 |
| Oxycodone Hcl | Oxycodone Hcl | 388 | 49 |
| Alprazolam | Alprazolam | 378 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 309 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 50 |
| Losartan Potassium | Losartan Potassium | 199 | 60 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 194 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 49 |
| Gabapentin | Gabapentin | 168 | 40 |
| Jardiance | Empagliflozin | 156 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 45 |
| Lisinopril | Lisinopril | 141 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 35 |
| Trazodone Hcl | Trazodone Hcl | 132 | 28 |
| Telmisartan | Telmisartan | 120 | 27 |
| Meloxicam | Meloxicam | 118 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 40 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 114 | 11 |
| Omeprazole | Omeprazole | 103 | 30 |
| Eliquis | Apixaban | 100 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 15 |
| Tramadol Hcl | Tramadol Hcl | 98 | 20 |
| Metformin Hcl | Metformin Hcl | 92 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 26 |
| Furosemide | Furosemide | 88 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 21 |
| Potassium Chloride | Potassium Chloride | 80 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 19 |
| Celecoxib | Celecoxib | 74 | 11 |
| Ondansetron Odt | Ondansetron | 74 | 12 |
| Pregabalin | Pregabalin | 74 | 15 |
| Prednisone | Prednisone | 71 | 38 |
| Glimepiride | Glimepiride | 70 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 68 | suppressed |
| Diazepam | Diazepam | 65 | suppressed |
| Lorazepam | Lorazepam | 62 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 62 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 16 |
| Ezetimibe | Ezetimibe | 60 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Metformin Hcl Er | Metformin Hcl | 57 | 15 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Spironolactone | Spironolactone | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Fenofibrate | Fenofibrate | 47 | suppressed |
| Ozempic | Semaglutide | 47 | 17 |
| Methocarbamol | Methocarbamol | 46 | 13 |
| Simvastatin | Simvastatin | 46 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | 13 |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 12 |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Felbamate | Felbamate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,734.48 · 105 records | ABBVIE INC. | CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FANAPT, HETLIOZ, Heplisav-B, IBSRELA, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Qelbree, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error